Viking Therapeutics, Inc. (VKTX) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
5.69
↑+24% vs avg
5yr avg: 4.59
30Y Low1.5·High7.8
ROE
↓
-47.3%
↑-44% vs avg
5yr avg: -32.9%
30Y Low-268%·High-9%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VKTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Viking Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.7B | $4.0B | $4.4B | $1.8B | $722M | $355M | $409M | $577M | $440M | $105M | $19M |
| Enterprise Value | $3.6B | $3.8B | $4.4B | $1.7B | $687M | $329M | $380M | $569M | $416M | $100M | $20M |
| P/E Ratio → | -10.12 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 5.69 | 6.20 | 4.98 | 5.04 | 4.97 | 1.76 | 1.67 | 2.08 | 1.48 | 7.83 | 2.41 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VKTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
VKTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -47.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -47.3% | -47.3% | -17.9% | -34.8% | -39.7% | -24.6% | -15.1% | -9.0% | -14.2% | -191.4% | -175.7% |
| ROA | -44.3% | -44.3% | -17.2% | -32.0% | -36.3% | -23.5% | -14.6% | -8.8% | -13.6% | -112.3% | -98.3% |
| ROIC | -44.4% | -44.4% | -19.7% | -37.4% | -36.9% | -21.4% | -13.2% | -9.0% | -14.0% | -177.0% | -113.2% |
| ROCE | -51.8% | -51.8% | -24.5% | -40.7% | -40.4% | -25.0% | -16.4% | -11.4% | -16.8% | -177.2% | -128.7% |
VKTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $166M exceeds total debt of $137000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | — | 0.26 | 0.41 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.26 | -0.03 | -0.16 | -0.24 | -0.13 | -0.12 | -0.03 | -0.08 | -0.41 | 0.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -7023.96 | -7023.96 | -1605.54 | -1145.76 | -1192.46 | -3093.44 | -371.59 | -175.57 | -38.26 | -9.55 | -6.25 |
Net cash position: cash ($166M) exceeds total debt ($137000)
VKTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Viking Therapeutics, Inc.'s current ratio of 9.33x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 19.19x to 9.33x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.33 | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 | 21.11 | 41.83 | 66.40 | 2.52 | 2.16 |
| Quick Ratio | 9.33 | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 | 21.11 | 41.83 | 66.40 | 2.52 | 2.16 |
| Cash Ratio | 9.21 | 9.21 | 32.93 | 18.92 | 7.08 | 23.02 | 20.48 | 40.67 | 66.27 | 2.38 | 2.03 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
VKTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Viking Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $113M | $109M | $94M | $77M | $77M | $73M | $72M | $58M | $26M | $16M |
Peer Comparison
Compare VKTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VKTXYou | $4B | -10.1 | — | — | — | — | -47.3% | -44.4% | — |
 TERN | $5B | -47.3 | — | — | — | — | -29.6% | -42.2% | — |
 PEPG | $127M | -0.9 | — | — | — | — | -67.4% | -73.2% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 GPCR | $2B | -17.0 | — | — | — | — | -11.9% | -30.3% | — |
 CGON | $6B | -32.7 | — | — | -15.0% | -4722.1% | -21.7% | -23.8% | — |
 NVO | $203B | 12.7 | 9.4 | 44.7 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 LLY | $933B | 43.0 | 31.0 | 104.0 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 AMGN | $179B | 23.3 | 14.1 | 22.1 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 RYTM | $7B | -31.1 | — | — | 89.7% | -101.2% | -129.5% | -70.1% | — |
 WTMA | $21M | 0.0 | — | — | — | — | -134.0% | -176.8% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See VKTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VKTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VKTX vs TERN
Side-by-side business, growth, and profitability comparison vs Terns Pharmaceuticals, Inc..
Start ComparisonVKTX — Frequently Asked Questions
Quick answers to the most common questions about buying VKTX stock.
What is Viking Therapeutics, Inc.'s P/E ratio?
Viking Therapeutics, Inc.'s current P/E ratio is -10.1x. This places it at the 50th percentile of its historical range.
What is Viking Therapeutics, Inc.'s ROE?
Viking Therapeutics, Inc.'s return on equity (ROE) is -47.3%. The historical average is -76.2%.
Is VKTX stock overvalued?
Based on historical data, Viking Therapeutics, Inc. is trading at a P/E of -10.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.